Publications
No. | Year | Title | Journal |
1 | 2021 | Computationally-guided design and affinity improvement of a protein binder targeting a specific site on HER2 | Computational and Structural Biotechnology Journal 2021 Feb 27;19:1325-1334 |
2 | 2020 | Effective inhibition of C3a‐mediated pro‐inflammatory response by a human C3a‐specific protein binder | Biotechnology and Bioengineering 2020 Jun;117(6):1904-1908 |
3 | 2020 | A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton’s tyrosine kinase and its drug-resistant variant | Biochemical and Biophysical Research Communications 2020 May 21;526(1):8-13 |
4 | 2019 | Computer-aided Binding Mode Prediction and Affinity Maturation of LRR Protein 2 Binder without Structural Determination | PLOS Computational Biology 2020 Aug 31;16(8):e1008150 |
5 | 2020 | A small-sized protein binder specific for human PD-1 effectively suppresses the tumor growth in tumor mouse model | Journal of Drug Targeting 2020 Apr;28(4):419-427 |
6 | 2019 | Prolonged half-life of small-sized therapeutic protein using serum albuminspecific protein binder | Journal of Controlled Release 2019 Dec 10;315:31-39 |
7 | 2018 | Engineering and cytosolic delivery of a native regulatory protein and its variants for modulation of ERK2 signaling pathway | Biotechnology and Bioengineering 2018 Apr;115(4):839-849 |
8 | 2017 | Intracellular protein delivery system using a target-specific repebody and translocation domain of bacterial exotoxin | ACS Chemical Biology 2017 Nov 17;12(11):2891-2897 |
9 | 2017 | A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors | Theranostics 2017 Jun 25;7(10):2620-2633 |
10 | 2016 | Effective suppression of C5a-induced proinflammatory response using anti-human C5a repebody | Biochemical and Biophysical Research Communications 2016 Sep 2;477(4):1072-1077 |
11 | 2016 | Engineering of bacterial exotoxins for highly efficient and receptor-specific intracellular delivery of diverse cargos | Biotechnology and Bioengineering 2016 Aug;113(8):1639-46 |
12 | 2016 | Anti-Human VEGF Repebody Effectively Suppresses Choroidal Neovascularization and Vascular Leakage | PLOS one 2016 Mar 25;11(3):e0152522 |
13 | 2015 | Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein–Drug Conjugates for Targeted Therapy | Angewandte Chemie 2015 Oct 5;54(41):12020-4 |
14 | 2014 | A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer | Molecular Therapy 2014 Jul;22(7):1254-1265 |
15 | 2014 | Protein Binder for Affinity Purification of Human Immunoglobulin Antibodies | Analytical Chemistry 2014 Jun 17;86(12):6019-25 |
16 | 2012 | Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering | PNAS 2012 Feb 28;109(9):3299-304 |
상호명 주식회사 프로엔테라퓨틱스 | 대표자 이일한
전화번호 031-759-8788 | 팩스번호 031-759-8850
이메일 proen@proentherapeutics.com
판교지사 경기도 성남시 수정구 청계산로 686 반도아이비밸리 301호
대전본사 대전광역시 유성구 테크노4로 17 대덕비즈센터 B동 204호
Copyright 2021. ProEn Therapeutics Inc. All Rights Reserved.
상호명 주식회사 프로엔테라퓨틱스 | 대표자 이일한
전화번호 031-759-8788 | 팩스번호 031-759-8850 | 이메일 proen@proentherapeutics.com
판교지사 경기도 성남시 수정구 청계산로 686 반도아이비밸리 301호 | 대전본사 대전광역시 유성구 테크노4로 17 대덕비즈센터 B동 204호
Copyright 2021. ProEn Therapeutics Inc. All Rights Reserved.